# PROSPECT-LUNG (NCT06632327)

> Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: nivolumab; pembrolizumab; atezolizumab
- Indication: stage II-IIIB resectable non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06632327
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Alliance for Clinical Trials in Oncology
- Conditions: Resectable Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8
- Interventions: Surgical Procedure; Cisplatin; Carboplatin; Pemetrexed; Gemcitabine; Docetaxel; Vinorelbine; Nivolumab; Pembrolizumab; Atezolizumab; Computed Tomography; Magnetic Resonance Imaging; Positron Emission Tomography
- Enrollment: 37
- Primary outcome: 3-year real-world event-free survival (rwEFS)
- Primary outcome: Overall survival (OS)

## Indexed commentary on PROSPECT-LUNG so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 7
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=prospect-lung-nct06632327

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06632327", "email": "<work email>"}; the inbox owner confirms by the emailed link.